Replies to post #377197 on Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

I wholeheartedly agree as well. Too much risk, but we don’t own all Adderall profit was my clarifying comment. At least not yet…

[imanjen13]

I also agree with BOD decision to defer buying Mikah position in Adderall until the success or failure to self distribute commencing in April can be evaluated.
I am interested in the status of the Doxycycline product which was codeveloped with Praxgen nee Sungen which was approved in April 2022 and Discontinued by Praxgen in August 2022 The yearly market is $85 million with 10 competitors. This drug would appear to be a good choice for Kirkov to market. Good question for NH to address on the conference call.
As the King, would you consider drafting a list of investor questions and emailing to Dianne? TIA.